Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant

Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant

HIV-1 is a chronic disease managed by strictly adhering to daily antiretroviral therapy (ART). However, not all people living with HIV-1 have access to ART, and those with access may not adhere to treatment regimens increasing viral load and disease progression. Here, a subcutaneous nanofluidic impl...

Full description

Bibliographic Details
Main Authors: Fernanda P. Pons-Faudoa, Nicola Di Trani, Antons Sizovs, Kathryn A. Shelton, Zoha Momin, Lane R. Bushman, Jiaqiong Xu, Dorothy E. Lewis, Sandra Demaria, Trevor Hawkins, James F. Rooney, Mark A. Marzinke, Jason T. Kimata, Peter L. Anderson, Pramod N. Nehete, Roberto C. Arduino, K. Jagannadha Sastry, Alessandro Grattoni
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Pharmaceutics
Subjects:
HIV treatment
implantable drug delivery
viral load
TAF monotherapy
long-acting TAF
Online Access:https://www.mdpi.com/1999-4923/12/10/981

Similar Items

Similar Items